<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879916</url>
  </required_header>
  <id_info>
    <org_study_id>11/20/162</org_study_id>
    <secondary_id>B300201111454</secondary_id>
    <nct_id>NCT02879916</nct_id>
  </id_info>
  <brief_title>Comparison of an Interscalene Nerve Block With or Without Stellate Ganglion Block for Shoulder Surgery</brief_title>
  <official_title>Comparison of the Analgesic Effect of Levobupivacaine 0.5% Via Interscalene Nerve Block or Via Interscalene Nerve Block Combined With a Stellate Ganglion Block in Patients Undergoing Shoulder Arthroscopy With General Anaesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study describes the difference of analgesic effect of levobupivacaine 0.5% administered
      through an interscalene nerve block with or without a stellate ganglion block. The length of
      the analgesic effect is our primary outcome parameter. Half of the recruited patients will
      receive a stellate ganglion block and half of the patients won't.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>The duration of analgesia assessed with quantitative sensory testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for rescue analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>The timing of the need for rescue analgesia as requested by the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of motor block</measure>
    <time_frame>24 hours</time_frame>
    <description>The duration of a motor block</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Anesthesia, Regional</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9% 3ml perineural stellate ganglion injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stellate ganglion block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levobupivacaine 3ml perineural stellate ganglion injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>Inject 3ml of levobupavacaine into the stellate ganglion area</description>
    <arm_group_label>Stellate ganglion block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <description>Inject 3ml of NaCl 0.9% into the stellate ganglion area</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA class 1 to 3

          -  Need for shoulder surgery

        Exclusion Criteria:

          -  Mental retardation

          -  allergy for local anesthetics

          -  a medical reason as a contra-indication for NSAID use

          -  Diabetes mellitus

          -  peripheral neuropathy

          -  chronic analgetic use

          -  chronic pain patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Sermeus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Tom Schepens, MD</investigator_full_name>
    <investigator_title>research assistant</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

